As Per Attachment
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 9.8 pts more than Nifty Microcap 250 and 9.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sanjivani Paranteral Ltd's board approved audited standalone and consolidated financial results for Q4 and FY ended 31st March 2025. Revenue from operations grew to Rs. 70.10 crores in FY25 from Rs. 54.41 crores in FY24, a rise of about 28.8%. Net profit jumped to Rs. 8.10 crores from Rs. 6.17 crores, up roughly 31.4%, with EPS rising to Rs. 6.89 from Rs. 5.28. The board recommended a final dividend of Rs. 0.50 per share (5%) subject to shareholder approval. Statutory auditor R.B. Gohil & Co. issued an unmodified (clean) opinion on the results. M/s. HD and Associates was appointed as Secretarial Auditor for five years from FY 2025-26.
Strong top-line and bottom-line growth along with a clean audit opinion are positive signals for shareholders. The dividend and expansion moves (new IV fluid plant in Pune, European nutraceutical joint venture) suggest confidence in future earnings, though standalone operating cashflow turned slightly negative and borrowings rose sharply, warranting a watch on working capital and debt levels.